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of GLP-1 on the ischemia-reperfusion-like effect
induced by hyperglycemia post-hypoglycemia in
type 1 diabetes
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Background: It has been reported that hyperglycemia following hypoglycemia produces an ischemia-
reperfusion-like effect in type 1 diabetes. In this study the possibility that GLP-1 has a protective effect on this
phenomenon has been tested.
Methods: 15 type 1 diabetic patients underwent to five experiments: a period of two hours of hypoglycemia
followed by two hours of normo-glycemia or hyperglycemia with the concomitant infusion of GLP-1 or vitamin C
or both. At baseline, after 2 and 4 hours, glycemia, plasma nitrotyrosine, plasma 8-iso prostaglandin F2alpha,
sCAM-1a, IL-6 and flow mediated vasodilation were measured.
Results: After 2 h of hypoglycemia, flow mediated vasodilation significantly decreased, while sICAM-1, 8-iso-PGF2a,
nitrotyrosine and IL-6 significantly increased. While recovering with normoglycemia was accompanied by a
significant improvement of endothelial dysfunction, oxidative stress and inflammation, a period of hyperglycemia
after hypoglycemia worsens all these parameters. These effects were counterbalanced by GLP-1 and better by
vitamin C, while the simultaneous infusion of both almost completely abolished the effect of hyperglycemia post
hypoglycemia.
Conclusions: This study shows that GLP-1 infusion, during induced hyperglycemia post hypoglycemia, reduces the
generation of oxidative stress and inflammation, improving the endothelial dysfunction, in type 1 diabetes.
Furthermore, the data support that vitamin C and GLP-1 may have an additive protective effect in such condition.
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It has recently been suggested that hypoglycemia may
play an important role in vascular complications of
diabetes [1].
Hypoglycemia causes oxidative stress [2], inflammation
[3] and endothelial dysfunction [4]. Oxidative stress is
considered the key player in the pathogenesis of diabetic
complications [5]. During hyperglycemia oxidative stress* Correspondence: aceriell@clinic.ub.es
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reproduction in any medium, provided the oris produced at the mitochondrial level [5], similarly as in
hypoglycemia [2]. Therefore, oxidative stress might be
considered the common factor linking hyperglycemia,
hypoglycemia and vascular complications of diabetes.
Consistent with this hypothesis is the evidence that both
hyperglycemia [6] and hypoglycemia produce endothelial
dysfunction and inflammation through the generation of
oxidative stress [4,7]. Both endothelial dysfunction and
inflammation are well-recognized pathogenic factors for
vascular disease, particularly in diabetes [8].
However, there is evidence that free radical production
rises not only during hypoglycemia, but particularly dur-
ing glucose reperfusion after hypoglycemia [9]. In bothLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline characteristics of the type 1 diabetic
patients
Sex 8M 7F
Age years 23.2 ± 3.1
BMI Kg/m2 23.9 ± 2.7
Duration of the disease/years 7.6 ± 1.5
HbA1c % 7.8 ± 0.2
HbA1c mmol/mol 61.7 ± 2.1
Resting diastolic blood pressure mm Hg 77.3 ± 1.4
Resting systolic blood pressure mm Hg 116.1 ± 1.6
Total cholesterol mmol/l 4.2 ± 0.3
Triglycerides mmol/l 1.2 ± 0.2
HDL-C mmol/l 1.4 ± 0.2
LDL-C mmol/l 2.2 ± 0.2
FMD % 6.8 ± 0.8
8-iso-PGF2a (pg/ml) 65.5 ± 45.2
Nitrotyrosine μmol/l 0.68 ± 0.03
sICAM-1a (ng/ml) 170.4 ± 10.7
IL-6 (pg/ml) 234.10 ± 14.1
Data are expressed as mean ± SE.
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ferent concentrations of glucose reperfusion has been
linked to a degree of superoxide production and neuronal
death that increased proportionally with glucose concen-
trations during the reperfusion period [9]. Consistently, it
has recently been demonstrated that in type 1 diabetes
hyperglycemia following hypoglycemia worsens endothe-
lial dysfunction and inflammation through the generation
of an oxidative stress [10]. These findings suggest that
hyperglycemia following hypoglycemia produces a “reper-
fusion”-like effect [11].
GLP-1 and its analogues are now being used as ther-
apy in patients with type 2 diabetes [12] in whom a de-
fect of GLP-1 secretion/action in response to the meal
has often been reported [13]. However, recently, a pos-
sible beneficial effect of GLP-1 analogues in the manage-
ment of also type 1 diabetes has been suggested [14].
GLP-1 analogues, in addition to their insulin-tropic ac-
tion, have beneficial effects in protecting pancreatic β-
cell function, in suppressing glucagon secretion and in
delaying gastric emptying, all characteristics which could
be beneficial for the management of type 1 diabetes [14].
Apart from the well-documented incretin effect of glu-
cagon like peptide 1 (GLP-1), its role in the cardiovascu-
lar system also arouses interest. GLP-1 effects on the
cardiovascular system may include a direct action on the
endothelium, where the presence of specific receptors
for GLP-1 has been demonstrated [15]. Consistently,
GLP-1 has demonstrated to improve endothelial func-
tion in diabetes [16,17]. This protective effect should be
exerted improving the antioxidant defenses of the endo-
thelium [18] and decreasing oxidative stress generation
[17]. Furthermore, GLP-1 seems to have a protective ef-
fect during ischemia/reperfusion of the heart [19].
Overall, the situation seems to be more complicated. It
has been demonstrated that in type 2 diabetes hypergly-
cemia induces a resistance to the action of GLP-1 at the
level of the β-cell, endothelium and muscle, being the
oxidative stress the mediator of such phenomenon
[13,17,20].
The aim of this study is to explore if GLP-1 can pro-
tect endothelial function and can reduce inflammation
when hypoglycemia is recovered with hyperglycemia,
and if this protective action is related to a decrease in
oxidative stress. Furthermore, to explore a possible ap-




Fifteen persons with type 1 diabetes were studied
(Table 1). They were treated with multiple daily insulin
injections, had normal bedside tests of autonomic func-
tion [17] and did not exhibit hypoglycemia unawarenessas based on the methods of Gold, et al. [18], as well as
had no major macro or micro complications of diabetes.
Subjects were excluded from the study if they had a his-
tory of at least one major episode of hypoglycemia in the
preceding 2 years. All subjects were nonsmokers and
had normal blood count, plasma lipids, plasma electro-
lytes, liver and renal function, and blood pressure. No
subject was taking medications known to affect neuroen-
docrine responses to hypoglycemia or inflammation.
Studies were approved by the Ethics Committees of the
respective research institutions involved, and all partici-
pants gave written informed consent.
All study patients were asked to avoid any exercise
and consume their usual weight-maintaining diet for
3 days before each experiment. All people with type 1 dia-
betes were asked to perform intensive home blood glucose
monitoring and to avoid hypoglycemia for at least 5 days
before the study. On the day prior to the study, intermedi-
ate or long-acting insulin was discontinued and replaced
with injections of regular insulin before breakfast and
lunch. Subjects were admitted to the research center the
evening before the experiment, at which time the individ-
uals with type 1 diabetes had two intravenous cannulas
inserted with 1% lidocaine local anesthesia. One cannula
was placed to be used for drawing blood, while the other
was placed in the contralateral arm for infusions. All sub-
jects received an evening meal and received a continuous
low-dose infusion of insulin to normalize plasma glucose.
The insulin infusion was adjusted overnight to maintain
blood glucose between 4.4 and 7.2 mmol/l.
Ceriello et al. Cardiovascular Diabetology 2013, 12:97 Page 3 of 7
http://www.cardiab.com/content/12/1/97Hypoglycemia experiments
Five different experiments, each following a two-hour
period of induced hypoglycemia and lasting for two hours,
were planned for each subject in a randomized order:
protocol 1, reaching and maintaining normoglycemia;
protocol 2, reaching and maintaining hyperglycemia;
protocol 3, reaching and maintaining hyperglycemia with
simultaneous infusion of vitamin C; protocol 4, reaching
and maintaining hyperglycemia with simultaneous infu-
sion of GLP-1; protocol 5, reaching and maintaining
hyperglycemia with simultaneous infusion of vitamin C
plus GLP-1. The randomization was carried out using a
computer-generated, random-number sequence. Each
subject underwent the experiments at two-weeks or lon-
ger intervals.
In each experiment, the subjects fasted overnight for
10 hours. In all experiments, after an initial steady state
period of 120 min, a 2 h hyperinsulinemic hypoglycemic
clamp was performed, with a primed constant (9.0 pmol •
kg − 1 • min − 1) infusion of insulin (Actrapid,
NovoNordisk, Copenhagen, Denmark). The rate of glu-
cose decrease was controlled (~0.08 mmol/min), and glu-
cose nadir (2.9 mmol/l) was achieved using a modification
of the glucose clamp technique. During the clamp period,
plasma glucose was measured every 5 min, and a 20% dex-
trose infusion was adjusted so that plasma glucose levels
were held constant at 2.9 ± 0.1 mmol/l [19]. Potassium
chloride (20 mmol/l) was infused during the clamp to
reduce insulin-induced hypokalemia. After this period
of induced hypoglycemia, common to all the experi-
ments, 20% dextrose infusion was adjusted in order to
reach and maintain normoglycemia (4.5 mmol/l), or to
reach and maintain hyperglycemia (15 mmol/l), or to reach
and maintain hyperglycemia with the simultaneous infu-
sion of vitamin C (Bracco, Milan, Italy) [30 mg/min, [10]],
or GLP-1 (Synthetic GLP-1 (7–36) amide, PolyPeptide La-
boratories, Wolfenbuttel, Germany) [0.4 pmol Kgˉ1 min ˉ1
[21]], or both, for additional 120 min.
At baseline and after 2 and 4 hours, blood samples were
withdrawn for biochemical assays (glycemia, plasma
nitrotyrosine and plasma 8-iso prostaglandin F2alpha (8-
iso-PGF2a), both markers of oxidative stress, ICAM-1a
and IL-6, markers of inflammation), while endothelial
function was measured by flow mediated dilation (FMD).
Biochemical and clinical measurements
Cholesterol, triglycerides, HDL-C, LDL-C and plasma
nitrotyrosine were measured according to [22]. Plasma
glucose was measured by the glucose-oxidase method,
HbA1c by HPLC. Plasma 8-iso-PGF2a (Cayman Chem-
ical, Ann Arbor, Michigan, U.S.A.), sICAM-1 (British
Bio-technology, Abington, Oxon, U.K.) and IL-6 (R&D
Systems, Minneapolis, MN, USA), were determined with
commercially available kits.Endothelial function
Endothelial function was evaluated measuring the FMD
of the brachial artery [10,17]. At the end of each test, the
subjects laid quietly for 15 min. Then, sublingual nitro-
glycerin (0.3 mg) was administered and 3 min later the
last measurements were performed. Response to nitrogly-
cerin was used as a measure of endothelium-independent
vasodilation.Statistical analysis
The sample size was selected according to previous
studies [3-10].
Data are expressed as means ± SE. The Kolmogorov-
Smirnov algorithm was used to determine whether each
variable had a normal distribution. Comparisons of base-
line data among the groups were performed using un-
paired Student’s t-test or Mann–Whitney U-test, where
indicated. The changes in variables during the tests were
assessed by one-way ANOVA with repeated measures or
Kolgorov- Smirnof test, where indicated. If differences
reached statistical significance, post hoc analyses with
two-tailed paired t test or Wilcoxon signed rank test for
paired comparisons were used to assess differences at in-
dividual time periods in the study. Statistical significance
was defined as p < 0.05.Results
Similarly to previous studies [4-6], after 2 h of hypo-
glycemia FMD significantly decreased, while sICAM-1,
8-iso-PGF2a, nitrotyrosine and IL-6 significantly in-
creased, compared to basal values (Figure 1).
As already reported [10], the way to recovery from
hypoglycemia, had a dramatic different effect when ob-
tained reaching normoglycemia or hyperglycemia.
Similarly to our previous study, after 2 h of recovering
in normoglycemia, FMD was still significantly decreased,
while sICAM-1, 8-iso-PGF2a, nitrotyrosine and IL-6 were
still significantly increased, compared to basal values
(Figure 1). However, after 2 h of recovering in hypergly-
cemia, FMD decreased, and sICAM-1, 8-iso-PGF2a,
nitrotyrosine and IL-6 were increased even more signifi-
cantly compared to basal as well as to the recovery in
normoglycemia (Figure 1).
When the recovery in hyperglycemia was accompanied
by the simultaneous infusion of GLP-1, all these phe-
nomena were significantly attenuated: FMD decreased
less, while sICAM-1, 8-iso-PGF2a, nitrotyrosine and IL-
6 were less increased (Figure 1). Vitamin C was even
more effective than GLP-1 in decreasing all these phe-
nomena (Figure 1). Finally, the simultaneous infusion of
GLP-1 and vitamin C completely abolished the deleteri-
ous effects of hyperglycemia following the hypoglycemia
(Figure 1).
p<0,01 vs Hypergl + Normogl
p<0,05 vs basal 
p<0,01 vs Hypogl + Hypergl + GLP-1
p<0,01 vs Hypogl + Hypergl
p<0,01 vs Hypogl + Hypergl + VitC
p<0,001 vs Hypogl + Hypergl
Figure 1 Glycemia, sICAM-1, flow-mediated dilation (FMD), nitrotyrosine, IL-6 and 8-iso-PGF2a in type 1 diabetes during
the experiments.
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fected in any of the experiments. The amount of insulin
infused during all the experiments was similar (AUC
75,200 ± 350 vs 75,320 ± 370 vs 75,140 ± 350 vs 75,280 ±
280 vs 75,370 ± 270 pmol).
Discussion
This study confirms our previous results that recovering
hypoglycemia with hyperglycemia worsens endothelial
function and inflammation, being oxidative stress gener-
ation the possible cause of this effect [10]. We and
others have previously suggested that hyperglycemia fol-
lowing hypoglycemia generates an ischemia/reperfusion
like situation, generating an oxidative stress [9,10]. The
role of the oxidative stress is also supported by the data
obtained infusing vitamin C.
In this study, for the first time, we report that GLP-1
can partly counterbalance this phenomenon. Recently,
the crucial role of GLP-1 in cardiovascular disease has
been suggested by both preclinical and clinical studies
[19]. It has been reported that GLP-1 may have cardio-
protective effects, being ale of reducing the ischemia/re-
perfusion injury and also cardiac dysfunction in various
animal models and humans [19,23]. Several mechanisms
may explain the effect of GLP-1 in reducing the damage
induced by the ischemia/reperfusion and, between them,
the possibility that GLP-1 can reduce oxidative stress and
can increase antioxidants, leading to decreased apoptosis
[24,25]. Therefore, it is reasonable that, in our study, GLP-
1 should, reducing oxidative stress generation, improve
endothelial dysfunction and inflammation generated by
hyperglycemia following hypoglycemia.
It is worthy of interest that vitamin C was more effica-
cious than GLP-1 in counterbalancing the effects of hy-
perglycemia post hypoglycemia and that only when both
vitamin C and GLP-1 were simultaneously infused this
effect is quite completely abolished. It is important to
underline how vitamin C and GLP-1 act as antioxidants.
Vitamin C has a scavenger action, which means that it
“captures” the free radicals when they are already gener-
ated [24-26]. GLP-1, as other compounds, increases the
intracellular antioxidant defenses. This means that they
can cooperate on the global oxidative stress generated,
because they have a complimentary action. The data
show that, even vitamin C has been infused at the sup-
posed maximal antioxidant effect, the alterations in
endothelial function and inflammation are still persist-
ent even improved. This means, in our opinion, that
some “oxidative stress” still escapes from the action of
vitamin C. In this view, it is reasonable that adding
another antioxidant, such as GLP-1, which works as
antioxidant in a very different way, the effect on oxida-
tive stress and on its related alteration can be further
improved.A possible influence of insulin by itself on the results
cannot be excluded, particularly because it has recently
been reported that GLP-1 enhances the vasodilator ef-
fect of insulin [27]. However, in our experiments, the
amount of insulin infused was the same during all the
experiments, therefore, the role of insulin in the study
has certainly been minimized. In the same paper by
Tesauro et al. [27], GLP-1 was unable to enhance the
effect of vitamin C on endothelial dysfunction. However,
our experimental conditions are very different. We
studied fifteen people with type 1 diabetes, while the
study of Tesauro was focused on only five people with
the metabolic syndrome [27]. Moreover, as underlined
by the same authors, no control study, with vitamin C
alone, were performed.
It is also worthy of interest the recent report demon-
strating that three months of exenatide therapy had
similar effects on microvascular endothelial function,
markers of inflammation, oxidative stress, and vascular
activation, as metformin, in patients with obesity and
pre-diabetes [28], which could question the specific role
of GLP-1 analogues in preserving endothelial function.
However, it is important to underline that also metfor-
min, as GLP-1 [29], has an antioxidant power. Therefore
this similarity of the effect between the two compounds
could may explain the results of this study.
In our opinion this report has also important practical
implications. The risk of a cardiovascular disease in type
1 diabetes is very high [30], and the role of the oxidative
stress seems to very relevant in the pathogenesis of these
complications in type 1 diabetes [5]. The interest in un-
derstanding if hypoglycemia, which produces an oxida-
tive stress [1,2], is a risk factor for cardiovascular disease
in type 1 diabetes is increasing, even the epidemiological
data are quite conflicting [31-33]. We have already sug-
gested the hypothesis that the way in which recovery
from hypoglycemia takes place, because may increase
the oxidative stress, may condition the cardiovascular
outcomes [10]. It is currently suggested that GLP-1 ana-
logues could be helpful in the management of type 1
diabetes, not only because can contribute to improve
the metabolic control and to reduce insulin requirement
[14], but also because GLP-1 can protect type 1 diabetes
from hyperglycemia and hypoglycemia-induced oxida-
tive stress, inflammation and endothelial dysfunction
[34]. Our data suggest that another potential good rea-
son to use GLP-1 analogues in the management of type
1 diabetes might be related to their potential to reduce
oxidative stress, generated during hyperglycemia follow-
ing hypoglycemia.
In conclusion, this study confirming the possibility
that vitamin C counterbalances the deleterious effects of
hyperglycemia post-hypoglycemia underlines the role of
the oxidative stress in this phenomenon. At the same
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the deleterious effect of the ischemia/reperfusion induced
by the recovery from hypoglycemia with hyperglycemia,
on oxidative stress generation, inflammation and endothe-
lial dysfunction, supports the usefulness of GLP-1 and its
analogues in the management of type 1diabetes.
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